TESARO Inc  

(Public, NASDAQ:TSRO)   Watch this stock  
Find more results for TIMOTHY PEARSON
53.39
+1.16 (2.22%)
Feb 26 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 50.50 - 53.55
52 week 22.15 - 53.55
Open 52.00
Vol / Avg. 0.00/391,672.00
Mkt cap 1.90B
P/E     -
Div/yield     -
EPS -4.79
Shares 36.11M
Beta     -
Inst. own 104%
Apr 28, 2015
Q1 2015 TESARO Inc Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
Feb 19, 2015
Q4 2014 TESARO Inc Earnings Call - Webcast
Feb 19, 2015
Q4 2014 TESARO Inc Earnings Release
Feb 12, 2015
TESARO Inc at Leerink Global Healthcare Conference
Dec 2, 2014
TESARO Inc at Deutsche Bank BioFEST
Dec 2, 2014
TESARO Inc at NASDAQ OMX Investor Program
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '14) 2014
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -67.79% -85.62%
Return on average equity -131.61% -138.35%
Employees 108 -
CDP Score - -

Address

SUITE 3300, 1000 WINTER STREET
WALTHAM, MA 02451
United States - Map
+1-339-9700900 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

TESARO, Inc. (TESARO) is oncology-focused biopharmaceutical company dedicated to improving the lives of cancer patients. The Company acquires, in-licenses and develops oncology product candidates and commercializes these products globally. The Company´┐Żs Rolapitant is a potent and long-acting neurokinin-1, or NK-1, receptor antagonist for the prevention of chemotherapy induced nausea and vomiting (CINV); Niraparib, formerly known as MK-4827, is an orally active and potent poly (ADP-ribose) polymerase, and TSR-011 is an orally available targeted anti-cancer agent which is a potent inhibitor of both anaplastic lymphoma kinase (ALK) and tropomyosin-related kinase (TRK).

Officers and directors

David M. Mott Independent Chairman of the Board
Age: 49
Bio & Compensation  - Reuters
Mary Lynne Hedley Ph.D. President, Chief Operating Officer, Director
Age: 51
Bio & Compensation  - Reuters
Leon O. Moulder Jr. Chief Executive Officer, Director
Age: 56
Bio & Compensation  - Reuters
Timothy R. Pearson Chief Financial Officer, Executive Vice President
Age: 46
Bio & Compensation  - Reuters
Lawrence M. Alleva Independent Director
Age: 64
Bio & Compensation  - Reuters
James O. Armitage M.D. Independent Director
Age: 67
Bio & Compensation  - Reuters
Earl M. Collier Jr., Esq. Independent Director
Age: 65
Bio & Compensation  - Reuters
Arnold L. Oronsky Ph.D. Independent Director
Age: 74
Bio & Compensation  - Reuters
Beth C. Seidenberg M.D. Independent Director
Age: 55
Bio & Compensation  - Reuters